Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Genscript Biotech ( (HK:1548) ) is now available.
Genscript Biotech announced that its associate, Legend Biotech Corporation, has filed first-quarter 2026 financial results and business highlights with the U.S. securities regulator, directing investors to consult the official filing for full details. The company emphasized that the reported figures belong solely to Legend, not Genscript, and urged shareholders and potential investors to remain mindful of investment risks and exercise caution when trading Genscript’s securities.
The disclosure underscores Genscript’s transparency regarding developments at its associate while clarifying the separation between Legend’s financial performance and its own. By formally updating the market on Legend’s latest results, Genscript signals ongoing engagement with investors and reinforces risk awareness, potentially influencing how stakeholders assess the indirect impact of Legend’s operational progress on Genscript’s broader investment profile.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$15.50 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a Cayman Islands–incorporated biotech company listed in Hong Kong, with a focus on life sciences and biopharmaceuticals. The group holds an associate stake in Legend Biotech Corporation, a Nasdaq-listed biotechnology firm, reflecting Genscript’s exposure to global cell and gene therapy markets and related innovation-driven revenue streams.
Average Trading Volume: 9,445,323
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.11B
See more insights into 1548 stock on TipRanks’ Stock Analysis page.